ClinicaliQ Trial Snapshot
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn’s Disease — Recruiting • Phase III • Gastroenterology • NCT06819891.
- This trial tests a new drug called Afimkibart to treat moderate-to-severe Crohn's disease, comparing it against placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD). Conditions: Moderately to Severely Active Crohns Disease Interventions: Afimkibart, Placebo Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 425 participants